Skip to content

Standard routine treatment vs probiotics with standard routine treatment for allergic rhinitis

Study on the effects of probiotics lactobacillus fermentum and paracasei in adult allergic rhinitis patients in a tertiary care center - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058667
Enrollment
90
Registered
2023-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: probiotics(lactobacillus fementum and lactobacillus paracasei): study group will receive routine standard treatment for allergic rhinitis with probiotics (lactobacillus fermentum and l

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Adult Allergic rhinitis patients (age greater than 18 yrs ) reporting or being referred to the ENT OPD in TAGORE MEDICAL COLLEGE AND HOSPITAL and who gives consent for participation in the study

Exclusion criteria

Exclusion criteria: 1 Pregnant women and children’s 2 Age less than 18 yrs. 3 Patients already on steroid medications for known case of allergic rhinitis 4 Patients underwent endoscopic sinus surgeries 5 Immunocompromised individuals 6 Patients with chronic rhino sinusitis

Design outcomes

Primary

MeasureTime frame
Benefits includes direct improvement and resolution of symptoms of allergic rhinitis patientTimepoint: primary outcome assessed once in 4 weeks

Secondary

MeasureTime frame
Benefits includes faster direct improvement and resolution of symptoms of allergicTimepoint: Total duration of study assessment is 2 months for each patients

Countries

India

Contacts

Public ContactDr Anandkarthikeyan

Tagore medical college and hospital

anandkarthikeyan99@gmail.com7904864657

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026